Why Is MODERNA INC (MRNA) Stock Down Today?

Moderna Inc (MRNA) fell 5.77% to $149.66 in early trading on news of a $2 billion convertible senior notes offering. The offering, which matures in 2032 and pays no regular interest, is intended to fund corporate purposes, including debt repayment and oncology growth. The announcement triggered a sharp sell-off, with the stock opening at $145.69, a 2.7% gap down from the previous close.

What Happened

Moderna announced the proposed private placement of $2 billion in zero-coupon convertible senior notes due 2032. The offering is expected to generate proceeds that may be used for capped call transactions, oncology growth initiatives, and debt repayment. The move has raised concerns among investors about equity dilution and the company’s capital structure. The stock’s decline accelerated in the first minutes of trading, reaching a session low of $137.72 before stabilizing slightly. Options data from Cboe indicates mixed sentiment, with shares down 7.64% at one point.

What The Data Shows

The intraday session reflects a sharp and sustained decline, with volume of 0.4 million shares, far below the 3-month daily average. The stock opened with a significant gap down and has not recovered to its opening level. Over the past 8 trading sessions, the stock had surged 129.6%, from $64.46 to $148.00, but recent selling pressure has reversed much of that gain. Unusual options activity has also been observed, with $103.5 million in call premiums and $21.3 million in put premiums traded in the last 36 hours. The largest single options print totaled $12.2 million.

What To Watch

The stock is scheduled to report no earnings in the near term. Investors will likely monitor the breadth of coverage and sentiment shifts in the coming days, as well as the final terms of the offering.